Angiogenesis inhibitors in gastric and gastroesophageal junction cancer


Despite significant improvements in systemic chemotherapy during the past two decades, the prognosis of patients with advanced gastric and gastroesophageal junction adenocarcinoma remains poor. Because of molecular heterogeneity, it is essential to classify tumors based on the underlying oncogenic pathways and to develop targeted therapies acting on individual tumors. Unfortunately, although a number of molecular targets have been studied, very few of these agents can be used in a clinical setting. In this review, we summarize the available data on anti-angiogenic agents in advanced/metastatic gastric cancer.

DOI: 10.1007/s10120-015-0537-5

3 Figures and Tables

Cite this paper

@article{Roviello2015AngiogenesisII, title={Angiogenesis inhibitors in gastric and gastroesophageal junction cancer}, author={Giandomenico Roviello and Roberto Petrioli and Luigi Marano and Karol Polom and Daniele Marrelli and Armando Perrella and Franco Roviello}, journal={Gastric Cancer}, year={2015}, volume={19}, pages={31-41} }